PrimeRFP SCOUT · Federal Contract Recompete Brief

75A50324F63003Oseltamivir phosphate 75mg 10 CT blister — Alvogen Inc

Alvogen Inc holds $284.8M across 11 federal awards, concentrated at Department of Health and Human Services (HHS). This PIID sits alongside 1 related award under parent 75A50119D00035. Competition previously drew 8 offers. Recompete timing centers on the Sep 28, 2027 PoP end — agencies typically plan 12–18 months ahead.

Aspr/Orm-Sns

Awarding office

Alvogen Inc

Recipient

Sep 28, 2027

PoP end

$74.5M

Obligated

325412

NAICS

6505

PSC

8 bidders on last award

Watch this recompete

One email. No account. We ping you if the window moves.

Score my position vs Alvogen Inc — $90

Contract facts

Federal

Contract number75A50324F63003

Also listed as75A50119D00035-75A50324F63003

AgencyAspr/Orm-Sns

Awarding officeAspr/Orm-Sns

IncumbentAlvogen Inc

UEILJNNGDV77Y98

NAICS325412

No full NAICS 325412 intel page yet. Browse NAICS intelligence

PSC6505

Parent IDIQ / IDV75A50119D00035

Place of performanceMORRISTOWN, NJ

Related solicitation75A3234Q00019

PoP end (current)Sep 28, 2027

Obligated$74.5M

OSELTAMIVIR PHOSPHATE 75MG, 10 CT BLISTER (ADULT COURSE) is a federal award for Aspr/Orm-Sns held by Alvogen Inc. Estimated value $74.5M ($74.5M obligated). Current period of performance ends Sep 28, 2027. Last award drew 8 bidders. Place of performance: MORRISTOWN, NJ. Related solicitation 75A3234Q00019.

OSELTAMIVIR PHOSPHATE 75MG, 10 CT BLISTER (ADULT COURSE)

Recompete timing

Public

● Expiring in 404 days

Current PoP ends Sep 28, 2027 (404 days remaining). Agencies typically plan 12–18 months ahead — position before the PoP clock runs out.

Incumbent footprint

Public record

Alvogen Inc — $284.8M obligated across 11 awards (firm-wide, all agencies).

Sole agency: Department of Health and Human Services (HHS)

Department of Health and Human Services (HHS)$284.8M · 100% of firm total

Open full company profile →

Related awards

Same parent · incumbent

75A50325F80013

OSELTAMIVIR PHOSPHATE 75MG CAPSULES (NDC: 47781-470-13); 10 CT. BLISTERS PACKS AND OSELTAM…

$227.7M

Jun 29, 2027

Query this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP →

Frequently asked questions

What is contract 75A50324F63003?

75A50324F63003 (Oseltamivir phosphate 75mg 10 CT blister) is a Aspr/Orm-Sns award with an estimated value of $74.5M, currently held by Alvogen Inc. Figures are USASpending-sourced public-record facts plus SCOUT recompete analysis.

Which office awarded 75A50324F63003?

Aspr/Orm-Sns awarded 75A50324F63003 to Alvogen Inc.

Who is the incumbent on 75A50324F63003?

Alvogen Inc is the incumbent with $284.8M across 11 related awards in SCOUT’s public footprint. The current period of performance ends Sep 28, 2027.

When does Alvogen Inc’s 75A50324F63003 come up for recompete?

SCOUT tracks a period-of-performance end of Sep 28, 2027. Actual solicitation timing can shift with extensions, bridges, or consolidations.

Data: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows.

Data as of Aug 20, 2026 · refreshed monthlyLatest procurement action Apr 11, 2025